Drug Hunter Letters #3 – September 2022
This edition of Drug Hunter Letters highlights recent insightful communications from Drug Hunter readers, including: Simon Bury on the History of GSK’s Recently Acquired $1.9B JAK Inhibitor We recently published an article about why GSK acquired a JAK inhibitor for $1.9B from Cytopia. Simon Bury, Global Head of Business Development of SYNthesis Med Chem, shares…
Agile Drug Hunting
As biotech experts, risk taking is part of our business model. Without scientific and business risk, inventions would not occur and businesses would not grow. How do we know we are taking appropriate risks at the right time? How do we know we are using agile drug development strategies by tracking, understanding, and mitigating risk…
Beginning with the End in Mind: Five Minutes with a Commercial Leader
Product development is unique in biopharma in the degree of separation between product developers (R&D scientists) and end users (patients and practitioners). While R&D focuses on questions like “Is it possible to treat this disease?” and “How can we drug this target?”, commercial organizations focus on questions like “Why does a physician prescribe these drugs?”…
Shaken by An Unexpected Patient Connection
with Julien Lefranc We asked one of our reviewers, Julien Lefranc, about what inspires and excites him about drug discovery. Here, he tells us about an unexpected, moving connection with a cancer patient, and what drives him to work every day. About Julien Julien is a Principal Scientist at Merck KGaA in Darmstadt and is…
Highlights from Q1 2022 Webinar Part II
Thank you to all of the drug hunters who attended our second drug discovery webinar! You can find the video and slides at the bottom of this page. In part II of this series we covered: Emerging startups, growing drug discovery companies, and IPOs Clinical readouts, positive and negative Big deals and major regulatory actions…
Drug Hunter Letters #2: On Carboxylic Acids and Acylglucuronides
Recently, Dr. Alf Claesson (CEO of Awametox AB, inventor of SpotRM, and previously Principal Scientist and Section Head at AstraZeneca/Astra AB, Sweden) reached out about our resource on the bioactivation of structural alerts. Dr. Claesson shared the helpful notes that: Here Dr. Claesson elaborates on carboxylic acids in particular. On carboxylic acids and acylglucuronides in…